Use of direct oral anticoagulants in patients with atrialfibrillation and kidney failure

DOACs have been increasingly used for stroke prevention in patients with AF despite thelack of data evaluating their safety and efficacy in patients with kidney failure. Additionally,management is complicated in these patients given the increased risk of bleeding in thesetting of renal impairment. Given the complexities of management in this patient population, this area remains a topic ofdiscussion and requires further study to assess the risks and benefits of using theseanticoagulants for stroke prevention in patients with kidney failure.